US20160075993A1 - Medium for culturing stem cells - Google Patents

Medium for culturing stem cells Download PDF

Info

Publication number
US20160075993A1
US20160075993A1 US14/953,132 US201514953132A US2016075993A1 US 20160075993 A1 US20160075993 A1 US 20160075993A1 US 201514953132 A US201514953132 A US 201514953132A US 2016075993 A1 US2016075993 A1 US 2016075993A1
Authority
US
United States
Prior art keywords
albumin
fatty acid
medium
acid
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/953,132
Other languages
English (en)
Inventor
Yoko KURIYAMA
Shou SENDA
Yumi Ando
Tomomi Yoshida
Haruna SATO
Daisuke Ejima
Takayoshi Fujii
Masayo Date
Manabu Kitazawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of US20160075993A1 publication Critical patent/US20160075993A1/en
Assigned to AJINOMOTO CO., INC. reassignment AJINOMOTO CO., INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUJII, TAKAYOSHI, YOSHIDA, TOMOMI, DATE, MASAYO, EJIMA, DAISUKE, SATO, HARUNA, ANDO, YUMI, KITAZAWA, MANABU, KURIYAMA, Yoko, SENDA, Sho
Priority to US16/898,844 priority Critical patent/US11859205B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]

Definitions

  • the present invention relates to media for culturing stem cells, method for producing such a medium, and the like.
  • stem cells embryonic stem cells, induced pluripotent stem cells (iPS cell,) and the like
  • a medium containing a serum For example, fetal bovine serum (FBS) and the like are widely used for cell culture as an important additive for cell proliferation.
  • FBS fetal bovine serum
  • stem cells after such culturing are used for medical purposes, a xeno-derived component may become a source of infection with blood-borne pathogen or a xenoantigen.
  • culture results may be inconsistent due to a difference between serum lots. Therefore, it has become mainstream in recent years to use a medium having a clear chemical composition (chemically-defined medium) for culturing stem cells, and the development of a serum-free medium is ongoing.
  • albumin One of the highly important components for serum-free medium is albumin. Addition of albumin is expected to provide an effect of stably maintaining the medium property. Several kinds of albumin are commercially available for culturing cells. However, not all albumins provide an equivalent effect for cell culture, particularly the culture of stem cells, and the quality of albumin affects the culture results.
  • palmitic acid is reported to induce apoptosis of mesenchymal stem cells (see Endocrinology November 2012, 153(11), 5275-5284, which is incorporated herein by reference in its entirety), and there is a report that addition of a substance that inhibits oleic acid synthase in iPS cells results in accumulation of palmitic acid, which induces ER stress-apoptosis (see Cell Stem Cell 2013, 12, 167-179, which is incorporated herein by reference in its entirety).
  • WO 2013/006675 which is incorporated herein by reference in its entirety, describes that octanoic acid is used in a medium to stabilize albumin, and octanoic acid is harmful for culture of stem cells.
  • octanoic acid is used in a medium to stabilize albumin, and octanoic acid is harmful for culture of stem cells.
  • use of a long chain fatty acid for stabilization of albumin is not described, nor are there any data or description showing that a long chain fatty acid is more harmful for culture of stem cells than octanoic acid which is a middle chain fatty acid, and exerts an adverse influence on the maintenance of undifferentiation potency.
  • WO 2013/1343708 which is incorporated herein by reference in its entirety, describes that fatty acid-free albumin is contained in a medium for stem cells.
  • a medium for culturing stem cells comprising an albumin carrying a reduced amount of fatty acid.
  • a medium for culturing stem cells, wherein the amount of fatty acid to be carried is 0.1 mg to 0.65 mg per 1 g albumin.
  • fatty acid is at least one kind selected from the group consisting of oleic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid and arachidonic acid.
  • ES cell embryonic stem cell
  • iPS cell induced pluripotent stem cell
  • a method of culturing stem cells comprising a step of cultivating in the medium of any of (1) to (12).
  • the pluripotent stem cell is an embryonic stem cell (ES cell) or an induced pluripotent stem cell (iPS cell).
  • a method of selecting an albumin suitable for addition to a medium comprising a step of measuring the amount of fatty acid carried, and selecting an albumin carrying a reduced amount of fatty acid.
  • a method of producing a medium for culturing stem cells comprising preparing an albumin carrying a reduced amount of fatty acid by a fatty acid removal treatment, and adding the prepared albumin to a medium.
  • pluripotent stem cell is an embryonic stem cell (ES cell) or an induced pluripotent stem cell (iPS cell).
  • ES cell embryonic stem cell
  • iPS cell induced pluripotent stem cell
  • An additive for a medium for culturing stem cells comprising an albumin carrying 0.1 mg/g to 0.65 mg/g of fatty acid.
  • fatty acid is at least one kind selected from the group consisting of oleic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid and arachidonic acid.
  • pluripotent stem cell is an embryonic stem cell (ES cell) or an induced pluripotent stem cell (iPS cell).
  • ES cell embryonic stem cell
  • iPS cell induced pluripotent stem cell
  • a culture system of a stem cell comprising a step of cultivating in a medium comprising an albumin carrying a reduced amount of fatty acid, wherein the amount of the fatty acid to be carried is so selected as to enable maintenance of the stem cell in an undifferentiated state.
  • fatty acid is at least one kind selected from the group consisting of oleic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid and arachidonic acid.
  • pluripotent stem cell is an embryonic stem cell (ES cell) or an induced pluripotent stem cell (iPS cell).
  • ES cell embryonic stem cell
  • iPS cell induced pluripotent stem cell
  • a stem cell can be grown while maintaining an undifferentiated state. Furthermore, using the medium of the present invention, a stem cell can be efficiently grown. Consequently, the frequency of medium exchange during culture can be reduced, and the cost of stem cell culture can be decreased.
  • FIG. 1 shows culture results of stem cells in an albumin-added medium.
  • the left Figure shows one embodiment of a culture dish marked with culture results + in Table 1
  • the right Figure shows one embodiment of a culture dish marked with culture results ⁇ .
  • FIG. 2 shows measurement results of viable cell number when stem cells are cultured in a medium added with albumin adsorbing fatty acid.
  • FIG. 3 shows an influence of human serum-derived albumin at varying purification degrees on the growth of iPS cells.
  • FIG. 4 shows an influence of human serum-derived albumin re-carrying a different kind of fatty acid, on the growth of iPS cells.
  • the term “stem cell” means an immature cell having self-renewal capacity and differentiation/proliferation capacity.
  • the stem cell includes subpopulations such as pluripotent stem cell, multipotent stem cell, unipotent stem cell, and the like, according to the differentiation potency.
  • pluripotent stem cell means a cell capable of differentiating into any tissue or cell constituting living organisms.
  • multipotent stem cell means a cell capable of differentiating into plural, though not all, kinds of tissues and cells.
  • unipotent stem cell means a cell capable of differentiating into particular tissues and cells.
  • pluripotent stem cells examples include embryonic stem cells (ES cell), embryonic germ cell (EG cell), induced pluripotent stem cell (iPS cell) and the like. It is preferably embryonic stem cells (ES cell) or an induced pluripotent stem cell (iPS cell).
  • ES cell embryonic stem cells
  • iPS cell induced pluripotent stem cell
  • a stem cell established by cultivating an early embryo generated by nuclear transplantation of the nucleus of a somatic cell is also preferable as the pluripotent stem cell (see Nature, 385, 810 (1997); Science, 280, 1256 (1998); Nature Biotechnology, 17, 456 (1999); Nature, 394, 369 (1998); Nature Genetics, 22, 127 (1999); Proc. Natl. Acad. Sci.
  • pluripotent stem cell induced and selected by stress and stimulation on the cell is an example of the pluripotent stem cell.
  • multipotent stem cells examples include somatic stem cells such as mesenchymal stem cell, hematopoietic stem cell, neural stem cell, myeloid stem cell, germ line stem cell and the like, and the like.
  • the multipotent stem cell is preferably a mesenchymal stem cell, more preferably a bone marrow mesenchymal stem cell.
  • the mesenchymal stem cell broadly means a population of stem cells or progenitor cells thereof, which can differentiate into all or some of the mesenchymal cells such as osteoblast, chondroblast, lipoblast and the like.
  • the basal medium to be used in the present invention one known per se can be used depending on the kind of the stem cells, and is not particularly limited as long as it does not inhibit proliferation of the stem cells.
  • examples thereof include DMEM, EMEM, IMDM (Iscove's Modified Dulbecco's Medium), GMEM (Glasgow's MEM), RPMI-1640, ⁇ -MEM, Ham's Medium F-12, Ham's Medium F-10, Ham's Medium F12K, Medium 199, ATCC-CRCM30, DM-160, DM-201, BME, Fischer, McCoy's 5A, Leibovitz's L-15, RITC80-7, MCDB105, MCDB107, MCDB131, MCDB153, MCDB201, NCTC109, NCTC135, Waymouth's MB752/1, CMRL-1066, Williams' medium E, Brinster's BMOC-3 Medium, E8 medium (Nature Methods, 2011, 8, 4
  • the medium to be used in the present invention can contain an additive substance known per se.
  • the additive substance is not particularly limited as long as it does not inhibit proliferation of stem cells. Examples thereof include growth factor (e.g., insulin etc.), iron source (e.g., transferrin etc.), polyamines (e.g., putrescine etc.), mineral (e.g., sodium selenate etc.), saccharides (e.g., glucose etc.), organic acid (e.g., pyruvic acid, lactic acid etc.), amino acid (e.g., L-glutamine), reducing agent (e.g., 2-mercaptoethanol), vitamins (e.g., ascorbic acid, d-biotin etc.), steroid (e.g., ⁇ -estradiol, progesterone etc.), antibiotic (e.g., streptomycin, penicillin, gentamicin etc.), buffering agent (e.g., HEPES etc.) and the like.
  • additives that have
  • the medium to be used in the present invention may contain a serum.
  • Serum is not particularly limited as long as it is derived from an animal and does not inhibit the growth of stem cells.
  • Preferred is a mammal-derived serum (e.g., fetal bovine serum, human serum etc.).
  • the concentration of the serum may be any as long as it is within a concentration range known per se. However, a lower content of serum is more preferable, and the absence of serum is most preferable, since it is known that serum components also contain a differentiation factor of human ES cell, and the like, and the culture results may be inconsistent due to a difference between serum lots.
  • a xeno-derived component may become an infection source of blood-mediated pathogen or a xenoantigen. Therefore, the absence of serum is preferable.
  • a replacement additive of serum e.g., Knockout Serum Replacement (KSR) (Invitrogen), Chemically-defined Lipid concentrated (Gibco), Glutamax (Gibco) etc.
  • KSR Knockout Serum Replacement
  • Sibco Chemically-defined Lipid concentrated
  • Glutamax Gibco
  • the present invention provides a medium for culturing stem cells, which characteristically has a decreased fatty acid content (hereinafter to be also referred to as the medium of the present invention).
  • the medium of the present invention can be preferably used for proliferation of any stem cells, it is preferably used for proliferation of an embryonic stem cell or an induced pluripotent stem cell.
  • the medium of the present invention can be preferably used for proliferation of stem cells derived from any animals.
  • the stem cells cultured by using the medium of the present invention are, for example, pluripotent stem cells derived from rodents such as mouse, rat, hamster, guinea pig and the like, Lagomorpha such as rabbit and the like, Ungulata such as swine, bovine, goat, horse, sheep and the like, Carnivora such as dog, cat and the like, primates such as human, monkey, Macaca mulatta, marmoset, orangutan, chimpanzee and the like.
  • the medium of the present invention characteristically has a decreased fatty acid content.
  • the medium of the present invention characteristically contains an albumin carrying a reduced amount of fatty acid.
  • the albumin to be used in the present invention is not particularly limited as long as it is used for cell culture, and is directly added to a medium when the amount of fatty acid to be carried it already reduced, or added after a fatty acid removal treatment when the amount of fatty acid to be carried has not been reduced.
  • a fatty acid removal treatment of albumin is sometimes expressed as “purification” of albumin.
  • fatty acid examples include saturated fatty acid having 8 to 20 carbon atoms (e.g., palmitic acid, stearic acid) and unsaturated fatty acid having 16 to 20 carbon atoms (e.g., oleic acid, linoleic acid, linolenic acid, arachidonic acid).
  • saturated fatty acid having 8 to 20 carbon atoms e.g., palmitic acid, stearic acid
  • unsaturated fatty acid having 16 to 20 carbon atoms e.g., oleic acid, linoleic acid, linolenic acid, arachidonic acid.
  • the present inventors studied to determine whether an influence on the growth of stem cells varies depending on the kind of fatty acid to be carried by albumin. As a result, they have found that long chain fatty acid shows a higher growth inhibitory action on stem cells than middle chain fatty acid. Therefore, in the medium of the present invention, long chain fatty acid is preferably reduced.
  • the term “long chain fatty acid” means a fatty acid having 12 or more carbon number.
  • the long chain fatty acid to be reduced in the medium of the present invention is not particularly limited as long as it has an action to inhibit growth of stem cells.
  • Specific examples of the long chain fatty acid to be reduced include oleic acid, stearic acid, palmitic acid, linoleic acid, linolenic acid and arachidonic acid.
  • Preferable examples of the long chain fatty acid to be reduced include stearic acid, palmitic acid, linoleic acid, linolenic acid and arachidonic acid.
  • albumin examples include naturally-derived albumin such as ovalbumin, swine-derived albumin, bovine-derived albumin, human-derived albumin and the like, gene recombinant albumin such as bovine type, swine type, human type and the like, and the like.
  • Particularly preferable examples thereof include serum-derived albumin and human type gene recombinant albumin (recombinant human albumin (rHSA)). Of these, human serum-derived albumin is particularly preferable.
  • Albumin is a protein having a high ability to bind to various substances, and binds to trace elements such as calcium, zinc and the like, fatty acid, enzyme, hormone and the like.
  • serum-derived albumin binds to various substances contained in serum.
  • 1 molecule of albumin generally has an ability to bind to 2 molecules of fatty acid.
  • the fatty acid removal treatment of albumin is not particularly limited as long as it can reduce the amount of fatty acid carried by albumin, and a treatment with activated carbon (see J. Biological Chemistry 1968, 212(2), 173-181), an ion exchange treatment (see BioChim. Biophy. Acta 1970, 221, 376-378 and Biologics 1997, 25, 391-401), a heat treatment (see Brazilian journal of medicinal and biological research 1998, 31, 1383-1388) and the like can be mentioned. From the aspects of economic efficiency, convenience and the like, a treatment with activated carbon is preferable.
  • the amount of fatty acid carried by albumin can be measured by a method generally practiced in the pertinent field, or a method analogous thereto.
  • Examples thereof include methyl esterification of free fatty acid followed by detection by GC-MS, quantification by infrared spectroscopy and extraction method of Duncombe, ACS-ACOD method using acyl-CoA synthase (ACS) and acyl-CoA oxydase (ACOD) and the like.
  • a commercially available measurement kit can be utilized for any of these.
  • the treatment with activated carbon may be performed under any conditions as long as a desired effect can be obtained.
  • the treatment with activated carbon can be performed using 30 to 60 wt %, preferably 40 to 50 wt %, of activated carbon per weight of albumin.
  • the pH of the treatment with activated carbon is not particularly limited as long as a desired effect can be obtained, it is pH 3 to 8, preferably pH 3.7 to 7.3, more preferably pH 3.7 to 4.3 or pH 6.7 to 7.3.
  • a fatty acid removal treatment of albumin can also be preferably performed by ion exchange chromatography.
  • a specific method thereof includes dialyzing an albumin solution against 40 mM sodium phosphate buffer adjusted to near neutral pH, subjecting same to anion exchange chromatography column (e.g., DEAE sepharose FF (GE Healthcare Japan)) previously equilibrated with the same buffer, then applying a linear concentration gradient to the 80 mM sodium phosphate adjusted to near neutral pH in a 10-fold volume of the column volume, whereby albumin fraction not bound to fatty acid can be recovered.
  • anion exchange chromatography column e.g., DEAE sepharose FF (GE Healthcare Japan)
  • the amount of fatty acid carried by albumin in the present invention is reduced to a level at which stem cells can grow well.
  • the amount of fatty acid carried by albumin when a fatty acid removal treatment is not performed is, for example, about 14 mg/g.
  • the amount of fatty acid carried by albumin used in the present invention is preferably reduced to not more than 10 mg/g, more preferably not more than 6 mg/g, further more preferably substantially free of fatty acid.
  • substantially free of fatty acid means that albumin does not at all bind to fatty acid, or even if it does, it is less than the detection limit of the measurement method or measurement kit used for measuring the amount of fatty acid being carried.
  • the total amount thereof is preferably reduced to fall within the above-mentioned range.
  • the amount of fatty acid carried by albumin to be used in the medium of the present invention can be not more than 10 mg/g, more preferably not more than 6 mg/g and not less than 0.1 mg/g, based on the total weight of albumin.
  • the amount of fatty acid carried can be 0.1 mg/g to 0.8 mg/g, preferably 0.1 mg/g to 0.65 mg/g or 0.2 mg/g to 0.8 mg/g, more preferably 0.2 mg/g to 0.65 mg/g, most preferably 0.29 mg/g to 0.65 mg/g, based on the total weight of albumin.
  • the amount of fatty acid to be carried is, for example, the amount of fatty acid carried by albumin which can be achieved by a fatty acid removal treatment of albumin performed by a convenient method such as a treatment with activated carbon and the like.
  • the amount of fatty acid to be carried is within the aforementioned range, the growth of stem cells can be promoted as compared to the use of a medium containing albumin without a fatty acid removal treatment. Therefore, the time, labor, cost and the like necessary for preparing a medium can be reduced, and the amount of fatty acid to be carried, which is within said range, can be preferably adopted for a convenient and large-scale production of the medium of the present invention.
  • an amount of less than 0.1 mg/g of fatty acid carried by albumin can afford a desired effect
  • the amount of less than 0.1 mg/g of fatty acid to be carried requires, for example, a further fatty acid removal treatment by a method such as ion exchange chromatography and the like, thus requiring time, labor, cost and the like as compared to convenient methods such as a treatment with activated carbon and the like. Therefore, an amount of less than 0.1 mg/g of fatty acid carried by albumin is disadvantageous for a large-scale production of the medium of the present invention at an industrial level.
  • the total amount thereof is preferably reduced to fall within the above-mentioned range.
  • an albumin carrying a reduced amount of fatty acid to be added to a medium is not particularly limited as long as it is an amount generally added to a medium for cell culture, it is added to a basal medium for stem cell culture to a final concentration of 0 to 50 mg/mL, preferably 0.01 to 30 mg/mL, more preferably 0.05 to 10 mg/mL, further preferably 0.5 to 5 mg/mL, based on the total volume of the medium.
  • the medium of the present invention has a reduced fatty acid content of the medium as a whole.
  • the “reduced fatty acid content of the medium as a whole” is intended to mean that not only the amount of fatty acid bound to albumin but also the amount of free fatty acid are reduced. In a preferable embodiment, the amount of fatty acid bound to albumin is reduced.
  • the content of fatty acid in the medium is preferably not more than 60 ⁇ M, more preferably not more than 30 ⁇ M, further preferably not more than 10 ⁇ M, further more preferably not more than 9, 8, 7, 6, 5, 4, 3, 2 or 1 ⁇ M, based on the total volume of the medium, most preferably a concentration that does not exert a great influence on the concentration of fatty acid contained in the basal medium for culturing stem cells.
  • the concentration of fatty acid contained in the basal medium for culturing stem cells is, for example, about 0.3 ⁇ M and 0.15 ⁇ M in commercially available Ham's Medium F-12 and DMEM/Ham's Medium F-12.
  • Not exerting a great influence means remaining within 10-fold concentration change from the concentration of fatty acid contained in the basal medium for culturing stem cells. That is, not less than 0 ⁇ M, a concentration exceeding 0 ⁇ M, not less than 0.15 ⁇ M, not less than 0.3 ⁇ M, not less than 0.5 ⁇ M of fatty acid can be contained as long as it does not go beyond a 10-fold amount of the concentration of fatty acid contained in the basal medium for stem cell culture.
  • the fatty acid content can be measured according to the above-mentioned method for measuring the amount of fatty acid bound to albumin, and a measurement kit is also commercially available.
  • the total amount thereof is preferably reduced to fall within the above-mentioned range.
  • fatty acid examples include saturated fatty acid having 8 to 20 carbon atoms (e.g., palmitic acid, stearic acid) and unsaturated fatty acid having 16 to 20 carbon atoms (e.g., oleic acid, linoleic acid, linolenic acid, arachidonic acid).
  • saturated fatty acid having 8 to 20 carbon atoms e.g., palmitic acid, stearic acid
  • unsaturated fatty acid having 16 to 20 carbon atoms e.g., oleic acid, linoleic acid, linolenic acid, arachidonic acid.
  • the fatty acid to be reduced is long chain fatty acid (fatty acid having 12 or more carbon atoms), and specific examples thereof include oleic acid, stearic acid, palmitic acid, linoleic acid, linolenic acid and arachidonic acid. Specific preferable examples include stearic acid, palmitic acid, linoleic acid, linolenic acid and arachidonic acid.
  • a medium for culturing stem cells containing 0.1 mg to 0.65 mg of fatty acid to be carried per 1 g albumin is preferable. Furthermore, a medium for culturing stem cells, having a content of fatty acid in the medium of not more than 60 ⁇ M is preferable.
  • the present invention provides a method of producing a medium for culturing stem cells which characteristically has a reduced content of fatty acid (hereinafter to be also referred to as the production method of the present invention).
  • the production method of the present invention includes preparing an albumin carrying a reduced amount of fatty acid by a fatty acid removal treatment (step 1), and adding the prepared albumin to a medium (step 2).
  • Step 1 Step of Preparing an Albumin Carrying a Reduced Amount of Fatty Acid by a Fatty Acid Removal Treatment.
  • human-derived serum albumin and rHSA are subjected to a fatty acid removal treatment such as a treatment with activated carbon, an ion exchange treatment, a heat treatment and the like (preferably treatment with activated carbon) to prepare an albumin carrying a reduced amount of fatty acid (preferably the amount of fatty acid to be carried is not more than 10 mg/g, more preferably not more than 6 mg/g, based on the total amount of albumin, and further preferably, substantially no fatty acid is carried).
  • a fatty acid removal treatment such as a treatment with activated carbon, an ion exchange treatment, a heat treatment and the like (preferably treatment with activated carbon) to prepare an albumin carrying a reduced amount of fatty acid (preferably the amount of fatty acid to be carried is not more than 10 mg/g, more preferably not more than 6 mg/g, based on the total amount of albumin, and further preferably, substantially no fatty acid is carried).
  • Reduction of the amount of fatty acid carried can be confirmed by measuring the amount of fatty
  • the amount of the fatty acid carried by albumin can be not more than 10 mg/g, more preferably not more than 6 mg/g, and not less than 0.1 mg/g, based on the total amount of albumin.
  • the amount of the fatty acid to be carried can be 0.1 mg/g to 0.8 mg/g, preferably 0.1 mg/g to 0.65 mg/g or 0.2 mg/g to 0.8 mg/g, more preferably 0.2 mg/g to 0.65 mg/g, most preferably 0.29 mg/g to 0.65 mg/g, based on the total amount of albumin.
  • Step 2 Step of Adding the Albumin Carrying a Reduced Amount of Fatty Acid Obtained in the Above-Mentioned Step 1 to a Medium.
  • the medium of the present invention It can be performed according to the above-mentioned section of “the medium of the present invention”.
  • An albumin carrying a reduced amount of fatty acid is added to a medium (basal medium) to a final concentration of 0 to 50 mg/mL, preferably 0.01 to 30 mg/mL, more preferably 0.05 to 10 mg/mL, further preferably 0.5 to 5 mg/mL, based on the total volume of the medium.
  • a basal medium those exemplified in the above-mentioned section of “the medium of the present invention” can be similarly used.
  • the present invention provides a method of selecting an albumin suitable for addition to a medium (hereinafter to be also referred to as the selection method of the present invention).
  • the selection method of the present invention is a method including measuring the amount of fatty acid carried by albumin (step 1), and selecting an albumin carrying a reduced amount of fatty acid (step 2).
  • Step 1 Step of Measuring the Amount of Fatty Acid Carried by Albumin.
  • the medium of the present invention can be performed according to the above-mentioned section of “the medium of the present invention”. In brief, it can be performed by a method generally performed in the pertinent field or a method analogous thereto. Examples thereof include an extraction method of Duncombe, ACS-ACOD method using acyl-CoA synthase (ACS) and acyl-CoA oxydase (ACOD) and the like. A commercially available measurement kit can be utilized for any of these.
  • Step 2 Step of Selecting an Albumin Carrying a Reduced Amount of Fatty Acid.
  • an albumin carrying a reduced amount of fatty acid is selected.
  • the “albumin carrying a reduced amount of fatty acid” is an albumin preferably carrying not more than 10 mg/g, more preferably not more than 6 mg/g, of fatty acid, based on the total amount of albumin, further preferably substantially no fatty acid carried.
  • the amount of fatty acid carried by albumin can be not more than 10 mg/g, more preferably not more than 6 mg/g, and not less than 0.1 mg/g, based on the total amount of albumin.
  • the amount of fatty acid to be carried can be 0.1 mg/g to 0.8 mg/g, preferably 0.1 mg/g to 0.65 mg/g or 0.2 mg/g to 0.8 mg/g, more preferably 0.2 mg/g to 0.65 mg/g, most preferably 0.29 mg/g to 0.65 mg/g, based on the total amount of albumin.
  • the thus-selected “albumin carrying a reduced amount of fatty acid” is preferably added to a medium for culturing stem cells.
  • the present invention provides a method of culturing stem cells (hereinafter to be also referred to as the culture method of the present invention).
  • the culture method of the present invention includes a step of cultivating stem cells in the medium of the present invention.
  • a culture container to be used for the culture of stem cell is not particularly limited as long as stem cells can be cultured, a flask, tissue culture flask, dish, petri dish, tissue culture dish, multidish, microplate, microwell plate, multiplate, multiwell plate, microslide, chamber slide, Schale, tube, tray, culture bag, and roller bottle can be mentioned.
  • the culture container may be cell adhesive or cell non-adhesive, and is appropriately selected according to the object.
  • a cell adhesive culture container may be coated with any cell supporting substrate such as extracellular matrix (ECM) and the like, in an attempt to improve the adhesiveness of the culture container surface to a cell.
  • ECM extracellular matrix
  • the cell supporting substrate may be any substance aiming at adhesion of stem cell or feeder cell (when used).
  • culture temperature is not particularly limited, it can be about 30 to 40° C., preferably about 37° C.
  • the CO 2 concentration can be about 1 to 10%, preferably about 2 to 5%.
  • the oxygen partial pressure can be 1 to 10%.
  • the present invention also provides an additive for a medium for culturing stem cells, which contains an albumin carrying a reduced amount of fatty acid (in the present specification, sometimes to be referred to as “the additive of the present invention”).
  • the amount of fatty acid carried by albumin to be contained in the additive of the present invention is not more than 10 mg/g, more preferably not more than 6 mg/g, based on the total amount of albumin, and further preferably, substantially no fatty acid is contained.
  • the amount of fatty acid carried by albumin can be not more than 10 mg/g, more preferably not more than 6 mg/g, and not less than 0.1 mg/g, based on the total amount of albumin.
  • the amount of fatty acid to be carried can be 0.1 mg/g to 0.8 mg/g, preferably 0.1 mg/g to 0.65 mg/g, or 0.2 mg/g to 0.8 mg/g, more preferably 0.2 mg/g to 0.65 mg/g, most preferably 0.29 mg/g to 0.65 mg/g, based on the total amount of albumin.
  • the additive of the present invention can further contain an additive substance other than albumin as long as the desired effect is not impaired.
  • the additive substance is not particularly limited as long as it does not inhibit proliferation of stem cells. Examples thereof include growth factor (e.g., insulin etc.), iron source (e.g., transferrin etc.), polyamines (e.g., putrescine etc.), mineral (e.g., sodium selenate etc.), saccharides (e.g., glucose etc.), organic acid (e.g., pyruvic acid, lactic acid etc.), amino acid (e.g., L-glutamine), reducing agent (e.g., 2-mercaptoethanol), vitamins (e.g., ascorbic acid, d-biotin etc.), steroid (e.g., ⁇ -estradiol, progesterone etc.), antibiotic (e.g., streptomycin, penicillin, gentamicin etc.), buffering agent (e.g., HEPES etc.) and the
  • the content of albumin carrying a reduced amount of fatty acid in the additive of the present invention is not particularly limited as long as the desired effect is obtained and, examples thereof include 0.05 to 250 mg/mL, preferably 0.05 to 150 mg/mL, more preferably 0.25 to 50 mg/mL, further preferably 2.5 to 25 mg/mL.
  • the additive is added such that the final concentration of albumin in the medium is 0.01 to 50 mg/mL, preferably 0.01 to 30 mg/mL, more preferably 0.05 to 10 mg/mL, further preferably 0.5 to 5 mg/mL, based on the total volume of the medium, and can be preferably used for culturing stem cells.
  • the fatty acid that can be reduced in the additive of the present invention is as mentioned above, and the definition of stem cell in the additive of the present invention is also as mentioned above.
  • the present invention also provides a culture system of a stem cell, comprising a step of cultivating in a medium comprising an albumin carrying a reduced amount of fatty acid, wherein the amount of the fatty acid to be carried is so selected as to enable maintenance of the stem cell in an undifferentiated state (in the present specification, sometimes to be described as “the culture system of the present invention”).
  • stem cell in an undifferentiated state means that an amount of fatty acid to be carried which is within the range permitting growth of stem cell in an undifferentiated state is selected.
  • an amount of fatty acid to be carried which is within the range permitting that, preferably, the proportion of differentiated cells does not increase in the culture period, and stem cells are cultured while said proportion is maintained within about 10% at most, and more preferably, differentiated cells are not substantially mixed, stem cells are cultured in an undifferentiated state, and permitting growth of undifferentiated cells can be selected.
  • the undifferentiated state of stem cells can be confirmed by a method known per se, and examples thereof include methods such as confirmation by alkaline phosphatase staining, confirmation of undifferentiated marker protein positive rate by FACS, confirmation of colony by a microscope and the like.
  • methods such as confirmation by alkaline phosphatase staining, confirmation of undifferentiated marker protein positive rate by FACS, confirmation of colony by a microscope and the like.
  • cells judged by the method to be not in an undifferentiated state can be identified as differentiated cells.
  • the amount of fatty acid carried by albumin to be used for the culture system of the present invention is not particularly limited as long as it is reduced to an amount of fatty acid which is so selected as to enable maintenance of stem cells in an undifferentiated state.
  • examples thereof include an albumin carrying not more than 10 mg/g, more preferably not more than 6 mg/g, of fatty acid, based on the total amount of albumin, and still more preferably, an albumin carrying substantially no fatty acid.
  • the amount of fatty acid carried by albumin can be not more than 10 mg/g, more preferably not more than 6 mg/g, and not less than 0.1 mg/g, based on the total amount of albumin.
  • the amount of fatty acid to be carried can be 0.1 mg/g to 0.8 mg/g, preferably 0.1 mg/g to 0.65 mg/g or 0.2 mg/g to 0.8 mg/g, more preferably 0.2 mg/g to 0.65 mg/g, most preferably 0.29 mg/g to 0.65 mg/g, based on the total amount of albumin.
  • the fatty acid that can be reduced in the culture system of the present invention is as mentioned above, and the definition of stem cell in the culture system of the present invention is also as mentioned above.
  • phosphate buffer pH 7.2, 40 ml
  • activated carbon 5 g, manufactured by Wako Pure Chemical Industries, Ltd.
  • the mixture was centrifuged at 4° C., 11,900 rpm for 20 minutes.
  • the activated carbon sediment was removed by decantation, and the reaction mixture was filtered through a 0.22 ⁇ m syringe filter.
  • the filtered solution was diluted 100-fold, the absorbance was measured at wavelengths of 260 nm, 280 nm, 320 nm by UV absorption measuring apparatus UV1800 (manufactured by Shimadzu Corporation), and the concentration was calculated by calculation formula (A280-A320)/0.55 ⁇ 100.
  • iPS cell induced pluripotent stem cell
  • 201B7 strain purchased from iPS Academia Japan, Inc. was used.
  • Cell culture was performed under conditions of 5% CO 2 /37° C. and using a culture vessel (Nippon Becton Dickinson Company, Ltd., Falconculture petri dish or Falconculture plate) coated with a basal membrane matrix.
  • E8 composition (disclosed in Nature Methods, 2011, 8, 424-429, which is incorporated herein by reference in its entirety) currently considered to be the minimum composition for cultivating human pluripotent stem cells, and used for culture, from which the effect was studied.
  • a solution or powder corresponding to 10 mg of albumin was prepared to 200 ⁇ l with 1% brine, methanol (400 ⁇ l) and chloroform (200 ⁇ l) were added, and the mixture was shaken for 10 minutes. Chloroform (200 ⁇ l) and 1% brine (200 ⁇ l) were added, the mixture was shaken for 10 min and centrifuged at 10,000 rpm for 2 minutes, and the bottom layer was collected. The solvent in the obtained chloroform layer was dried to solidness to give a sample for assay.
  • the sample was dissolved in 2-propanol, and the amount of fatty acid was quantified based on oleic acid, by an analytical curve method and using a fatty acid measurement kit (LabAssayTM NEFA, manufactured by Wako Pure Chemical Industries, Ltd.).
  • the absorbance was measured using SH900 (CORONA ELECTRIC Co., Ltd.).
  • Human serum-derived albumin was added to a medium to a final concentration of 2.6 g/L, and the culture results of each albumin were compared.
  • Several kinds of albumins were subjected to a purification treatment (fatty acid removal treatment) to remove lipid. The culture period was 1 week.
  • 13,000 viable cells were seeded as single-cell per well of a 6-well plate.
  • As a basal membrane matrix a fragment containing an active domain of laminin 511, which was purchased from Osaka University, was applied at 5 ⁇ g/well.
  • Y-27632 was added (final concentration 10 ⁇ M, NACALAI TESQUE, INC.: 08945-84) to a medium to be used for seeding. From the next day, the cells were cultured in a medium free of Y-27632.
  • FIG. 1 shows the state after culture of the cells marked with + or ⁇ in the column of culture results.
  • albumin obtained from each of Nova Biologics, Sigma, Biocell Laboratories was added to the medium, the cells did not proliferate except a part thereof. However, when the albumin after a purification treatment was added to the medium, the cells proliferated.
  • the amount of fatty acid carried (fatty acid content) of all these albumins was measured to find the results shown in Table 1. From the above results, it was found that fatty acid bound to albumin inhibits normal cell proliferation.
  • Oleic acid (12.6 ⁇ l) was charged in a 15 ml falcon tube, and a solution of purified human serum albumin B (5.9 ml, 8.8%) was added. The solution was shaken at 37° C. for 3 hours, allowed to cool and filtered with a 0.22 ⁇ m syringe filter.
  • albumin adsorbed with oleic acid was obtained.
  • Experiment was performed using a medium containing the obtained albumin adsorbed with oleic acid at a final concentration of 2.6 g/L (concentration of oleic acid in the medium 196 ⁇ M).
  • palmitic acid As for palmitic acid, stearic acid, linoleic acid, linolenic acid and arachidonic acid, a similar treatment was performed using the fatty acids at a dose described in Table 2 and purified human serum albumin to give albumin adsorbed with various fatty acids, and media added with albumin adsorbed with various fatty acids were prepared.
  • the amount of fatty acid carried by albumin was not measured after the above-mentioned adsorption operation.
  • a solution or powder corresponding to 10 mg of albumin was prepared to 200 ⁇ l with 1% brine, methanol (400 ⁇ l) and chloroform (200 ⁇ l) were added, and the mixture was shaken for 10 minutes. Chloroform (200 ⁇ l) and 1% brine (200 ⁇ l) were added, the mixture was shaken for 10 minutes and centrifuged at 10,000 rpm for 2 minutes, and the bottom layer was collected. The solvent in the obtained chloroform layer was dried to solidness to give a sample for assay.
  • the sample was dissolved in 2-propanol, and the amount of fatty acid was quantified based on oleic acid, by an analytical curve method and using a fatty acid measurement kit (LabAssayTM NEFA, manufactured by Wako Pure Chemical Industries, Ltd.).
  • the absorbance was measured using SH900 (CORONA ELECTRIC Co., Ltd.).
  • the fatty acids added to the media, concentration of fatty acids added, and the content of fatty acid per 1 g albumin (amount of fatty acid carried) are shown in Table 2.
  • stem cells were cultured. The culture period was 1 week. 13,000 viable cells were single-cell seeded per well of a 6-well plate. As a basal membrane matrix, a fragment containing an active domain of laminin 511, which was purchased from Osaka University, was applied at 5 ⁇ g/well. Y-27632 was added (final concentration 10 ⁇ M) to a medium to be used for seeding. From the next day, the cells were cultured in a medium free of Y-27632.
  • the cells were detached from each well by TrypLE Select (Life Technologies: 12563-011), and the number of viable cells in the well was measured. The results are shown in FIG. 2 .
  • Addition of oleic acid and palmitic acid was found to suppress cell proliferation.
  • the suppressive effect was in proportion to the concentration of fatty acid added, and addition of a high concentration of fatty acid resulted in stronger suppression of cell proliferation. From the above-mentioned results, it was found that cell culture efficiency decreases in a manner dependent on the concentration of fatty acid adsorbed to albumin.
  • Group (I) Human serum albumin (Sigma) treated by a fatty acid removal treatment.
  • the amount of fatty acid carried is considered to be not more than 0.07 mg/g.
  • V Human serum-derived albumin (NOVA Biologics, INC.) was used after purifying with 13 wt % of activated carbon relative to the weight of albumin at pH 7. The measurement result of the amount of fatty acid carried was 1.86 mg/g.
  • iPS cells were cultured.
  • a 6-well plate coated with a fragment containing an active domain of laminin 511 at 5 ⁇ g/well (iMatrix-511 (Nippi, Incorporated)) as a basal membrane matrix was used.
  • iPS cells were single-cell seeded at 13,000 cells/well and cultured for 1 week.
  • Y-27632 NACALAI TESQUE, INC.: 08945-84 was added at a final concentration of 10 ⁇ M only to a medium to be used for seeding.
  • FIG. 3 shows mean of three independent experiments for each group.
  • the number of viable iPS cells becomes not less than about 3.0 ⁇ 10 5 cells when cultured for one week by this culture method.
  • groups (I) to (III) showed good cell proliferation with a cell count exceeding 3.0 ⁇ 10 5 .
  • groups (IV) and (V) showed a clear growth inhibitory action. Therefrom it is clear that iPS cells can proliferate well at least when the amount of fatty acid carried by albumin is not more than 0.65 mg/g.
  • Groups (I) to (III) were further cultured for 1 week after the above-mentioned culture, and the differentiation rate was measured by alkaliphosphatase (ALP) staining.
  • the differentiation rate (%) was calculated by ALP negative colony number/total colony number ⁇ 100 of each well.
  • the differentiation rates of groups (I), (II), and (III) were 0.4%, 1.5% and 2.6%, respectively. These numerical values can be said to be sufficiently low, which has demonstrated that all conditions are suitable for proliferating iPS cells while maintaining an undifferentiated state thereof. Similar results were also obtained by observation of colony under a microscope, and it was confirmed that a higher purification level of albumin leads to the maintenance of undifferentiated state of iPS cells at a higher rate.
  • Octanoic acid (18.3 ⁇ L) was charged in a 50 mL falcone tube, and a human serum albumin solution B (15 mL, 10%, Sigma) after a fatty acid removal treatment was added. The solution was shaken at 37° C. for 7 hours, left standing at 4° C. overnight, and filtered with a 0.22 ⁇ m syringe filter. In this way, an albumin re-adsorbed with octanoic acid was obtained.
  • the amount of fatty acid carried by albumin re-adsorbed with octanoic acid was measured, and the albumin after re-adsorption with octanoic acid and a purified albumin before re-adsorption and after a fatty acid removal treatment were appropriately mixed while adjusting the ratio such that the final concentration of octanoic acid in the medium was 28 ⁇ M or 57 ⁇ M.
  • the mixture was added to a medium such that the final concentration of albumin was 2.6 g/L.
  • oleic acid As for oleic acid, stearic acid, palmitic acid, linoleic acid, linolenic acid and arachidonic acid, re-adsorption of fatty acid was performed in the same manner. The final concentration in and the amount of addition to the medium are also the same.
  • iPS cells were single-cell seeded at 13,000 cells/well and cultured for 1 week.
  • Y-27632 NACALAI TESQUE, INC.: 08945-84 was added at a final concentration of 10 ⁇ M only to a medium to be used for seeding.
  • IFS cells were cultured using an albumin free of re-adsorption of fatty acid, i.e., albumin after a fatty acid removal treatment.
  • FIG. 4 shows mean of three independent experiments for each group.
  • Linoleic acid and linolenic acid had a strong proliferation inhibitory action on iPS cells, and the cells died by re-adsorption at 57 ⁇ M, and the proliferation of iPS cells was markedly suppressed even by re-adsorption at 28 ⁇ M, as compared to the positive control. Even when oleic acid was re-adsorbed, a concentration-dependent cell proliferation inhibitory action was found, and the number of viable cells was smaller than that of the positive control for both 28 ⁇ M and 57 ⁇ M.
  • long chain fatty acids such as oleic acid and the like have strong toxicity to iPS cells and a high proliferation inhibitory action as compared to middle fatty acids such as octanoic acid and the like.
  • stem cells can be proliferated while maintaining an undifferentiated state. Furthermore, using the medium of the present invention, stem cells can be efficiently proliferated, the frequency of exchange of culture medium can be reduced, and the culture cost of stem cells can be decreased.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
US14/953,132 2013-05-30 2015-11-27 Medium for culturing stem cells Abandoned US20160075993A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/898,844 US11859205B2 (en) 2013-05-30 2020-06-11 Medium for culturing stem cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-114285 2013-05-30
JP2013114285 2013-05-30
PCT/JP2014/064497 WO2014192938A1 (ja) 2013-05-30 2014-05-30 幹細胞の培養用培地

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/064497 Continuation WO2014192938A1 (ja) 2013-05-30 2014-05-30 幹細胞の培養用培地

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/898,844 Division US11859205B2 (en) 2013-05-30 2020-06-11 Medium for culturing stem cells

Publications (1)

Publication Number Publication Date
US20160075993A1 true US20160075993A1 (en) 2016-03-17

Family

ID=51988956

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/953,132 Abandoned US20160075993A1 (en) 2013-05-30 2015-11-27 Medium for culturing stem cells
US16/898,844 Active 2035-08-09 US11859205B2 (en) 2013-05-30 2020-06-11 Medium for culturing stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/898,844 Active 2035-08-09 US11859205B2 (en) 2013-05-30 2020-06-11 Medium for culturing stem cells

Country Status (8)

Country Link
US (2) US20160075993A1 (de)
EP (1) EP3006558B1 (de)
JP (1) JP6634822B2 (de)
KR (1) KR102229266B1 (de)
CN (1) CN105283541B (de)
CA (1) CA2913990C (de)
SG (1) SG11201509767UA (de)
WO (1) WO2014192938A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6780638B2 (ja) * 2015-03-30 2020-11-04 味の素株式会社 ヒト血清アルブミンを含む神経幹細胞増殖培地
EP3571290B1 (de) * 2017-01-23 2024-04-10 Stemcell Technologies Canada Inc. Medien und verfahren zur erhöhung des überlebens und der proliferation von stammzellen
CN112368368B (zh) * 2018-06-15 2024-01-30 扶桑药品工业株式会社 辅助生殖医疗用培养基
US20220290097A1 (en) * 2019-08-03 2022-09-15 Shenzhen Mytang Biotechnology Co., Ltd. Poultry Egg-Based Culture Medium
KR20230005830A (ko) 2020-04-30 2023-01-10 오리엔탈 이스트 컴파니 리미티드 줄기세포용 배지 및 줄기세포의 배양 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130029418A1 (en) * 2011-12-05 2013-01-31 Matthew Angel Methods and products for transfection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004026917D1 (de) * 2003-12-26 2010-06-10 Makoto Asashima Basalmedium zur kultivierung von es-zellen
CA2643478C (en) 2006-02-23 2019-06-18 Novocell, Inc. Compositions and methods useful for culturing differentiable cells
GB0613756D0 (en) 2006-07-12 2006-08-23 Univ Sheffield Cell culture medium
CN101121753B (zh) * 2007-06-06 2011-11-16 天津林达生物科技有限公司 对多种皮肤细胞修复具持续作用的人血清白蛋白重组融合蛋白
CN107603943B (zh) * 2009-04-27 2019-10-11 威盛细胞有限公司 支持多能细胞生长的小分子和其方法
FI20096288A0 (fi) * 2009-12-04 2009-12-04 Kristiina Rajala Formulations and methods for culturing stem cells
CA2820419A1 (en) * 2010-12-08 2012-06-14 Viacyte, Inc. Agents and methods for inhibiting human pluripotent stem cell growth
JP6148429B2 (ja) * 2011-01-31 2017-06-14 協和発酵バイオ株式会社 ヒト多能性幹細胞の培養方法
WO2013006675A1 (en) 2011-07-05 2013-01-10 Novozymes Biopharma Uk Limited Albumin formulation and use
KR20140131999A (ko) 2012-03-07 2014-11-14 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 증폭 및 유지를 위한 한정 배지
WO2014119219A1 (ja) 2013-01-31 2014-08-07 味の素株式会社 多能性幹細胞の安定した未分化維持増殖を行うための培養方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130029418A1 (en) * 2011-12-05 2013-01-31 Matthew Angel Methods and products for transfection
US20130344602A1 (en) * 2011-12-05 2013-12-26 Factor Bioscience, Inc. Methods and products for transfection

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same

Also Published As

Publication number Publication date
KR20160012224A (ko) 2016-02-02
EP3006558B1 (de) 2020-05-13
US20200370006A1 (en) 2020-11-26
SG11201509767UA (en) 2015-12-30
CA2913990C (en) 2021-10-12
US11859205B2 (en) 2024-01-02
CN105283541B (zh) 2019-02-19
CA2913990A1 (en) 2014-12-04
EP3006558A1 (de) 2016-04-13
EP3006558A4 (de) 2016-11-23
CN105283541A (zh) 2016-01-27
JPWO2014192938A1 (ja) 2017-02-23
KR102229266B1 (ko) 2021-03-19
WO2014192938A1 (ja) 2014-12-04
JP6634822B2 (ja) 2020-01-22

Similar Documents

Publication Publication Date Title
US11859205B2 (en) Medium for culturing stem cells
US10457911B2 (en) Medium for stem cell use
US10947508B2 (en) Culture medium for mesenchymal stem cells
JP6744084B2 (ja) 幹細胞由来の分化細胞用培地、幹細胞からの分化細胞の製造及び該分化細胞を含む細胞医薬組成物の製造のための方法
US20200040308A1 (en) Additive for undifferentiation maintaining medium
JP6981403B2 (ja) 神経分化能を亢進させる神経幹細胞用培地

Legal Events

Date Code Title Description
AS Assignment

Owner name: AJINOMOTO CO., INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KURIYAMA, YOKO;SENDA, SHO;ANDO, YUMI;AND OTHERS;SIGNING DATES FROM 20160121 TO 20160128;REEL/FRAME:038415/0942

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION